DDInter1164 DDInter1435
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Metformin {u} (Compound) treats {v} (Disease) polycystic ovary syndrome
Metformin {u} (Compound) binds {v} (Gene) NDUFS8
Metformin {u} (Compound) upregulates {v} (Gene) SLC25A4
Metformin {u} (Compound) is included by {v} (Pharmacologic Class) Biguanides
Metformin {u} (Compound) downregulates {v} (Gene) TOMM34
Metformin {u} (Compound) causes {v} (Side Effect) Asthenia
Metformin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Metformin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Memantine
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Metformin (Compound) treats polycystic ovary syndrome (Disease)
Metformin (Compound) binds NDUFS8 (Gene)
Metformin (Compound) upregulates SLC25A4 (Gene)
Metformin (Compound) is included by Biguanides (Pharmacologic Class)
Metformin (Compound) downregulates TOMM34 (Gene)
Metformin (Compound) causes Asthenia (Side Effect)
Metformin may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Metformin may cause a minor interaction that can limit clinical effects when taken with Memantine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro